XIG: FHIR Resources

FHIR IG Statistics: FHIR Resources

Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
Authority: All | hl7 | ihe | national
Realm: All | BNW | au | be | br | ca | ch | cl | cr | cz | de | dk | ee | eu | fi | fr | il | in | it | jp | kr | nl | no | nz | pl | se | sl | stt | tw | uk | us | uv | vn
View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps

Resources - All Kinds

75,411 resources

By Version

R2: 0
R2B: 0
R3: 3,448
R4: 55,341
R4B: 3,134
R5: 13,264
R6: 224

By Authority

none: 25,640
hl7: 42,405
ihe: 1,382
national: 3,470
who: 2,514

By Realm

none: 22,398
au: 648
be: 387
br: 299
ca: 764
ch: 1,527
cl: 469
cr: 45
cz: 384
de: 2,066
dk: 1,474
ee: 276
eu: 1,253
fi: 87
fr: 1,545
il: 308
in: 163
it: 181
jp: 293
kr: 5
nl: 2,153
no: 26
nz: 79
pl: 83
se: 29
sl: 2
stt: 116
tw: 901
uk: 97
us: 19,481
uv: 17,592
vn: 107
other: 7

Start Prev Rows 51400 - 51600 Next

Package	Version	Identity	Name/Title	Status	Date	Realm	Auth
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.4	Nephrectomy	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.8	Large Body Surface Area (BSA) Burns	active	2022-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1250.2	Psychological Neuropsychological or Neurobehavioral Testing	active	2023-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1250.3	Psychological or Neuropsychological Testing	active	2023-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1251.10	Tricuspid Valve Regurgitation	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1251.2	Valvular Heart Disease	active	2022-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1258.1	Gonorrhea Screening	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1258.2	Abnormal Weight Loss	active	2024-10	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.2	Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetes	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.3	Prescribable brand and generic insulins and analogues	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.4	eGFR Using 2021 Race Free Formulas	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.5	Fructosamine in Serum or Plasma	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.6	Glucose tests in venous blood, capillary blood, serum/plasma for Diabetes	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.7	Creatinine in serum/plasma	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.9	IgE Agonists, prescribable	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.10	Estrogen Receptor Testing for Orserdu	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.100	MMR Proficient	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.101	Systemic Cancer Directed Therapy	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.102	Face To Face Interaction	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.104	Erdafitinib	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.107	Chemotherapy Encounter	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.108	Urothelial Cancers ICD9	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.109	Urothelial Cancer ICD10	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.110	Urothelial Cancers	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.111	Prior Therapies for Erdafitinib	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.112	Urothelial Cancer Histologies	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.113	Malignant Tumor Behavior	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.114	Localized Bladder Cancer Stage SNOMED	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.116	Localized Bladder Cancer Staging	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.117	Advanced Bladder Cancer Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.118	Localized Bladder Cancer T Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.119	Localized Bladder Cancer T Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.120	Localized Bladder Cancer N Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.121	Localized Bladder Cancer M Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.122	Advanced Bladder Cancer M Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.124	Locoregional Urothelial Cancer ICD9	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.125	Locoregional Urothelial Cancer ICD10	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.126	Locoregional Urothelial Cancer SNOMED	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.127	Locoregional Urothelial Cancer	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.128	FGFR3 Gene	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.129	FGFR3 Gene Interpretation Positive SNOMED	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.130	FGFR3 Gene Interpretation Positive LOINC	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.131	FGFR3 Gene Interpretation Positive NCI	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.133	FGFR3 Gene Interpretation Positive	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.134	FGFR3 Gene Interpretation Negative SNOMED	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.135	FGFR3 Gene Interpretation Negative NCI	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.137	FGFR3 Gene Interpretation Negative	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.138	FGFR3 Molecular Variants	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.139	Tumor Behavior	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.140	Physcological Support for Cancer	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.141	Referral For Pain From Cancer	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.142	Cancer Pain Education	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.143	Telehealth Encounters	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.144	Pain Assessment Score	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.146	Telehealth Encounters SNOMEDCT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.147	Telehealth Encounters CPT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.148	Telehealth Encounters HCPCS	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.149	Telehealth Encounters All	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.150	Chemo Admin SNOMEDCT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.151	Chemo Admin CPT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.152	Chemo Admin HCPCS	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.153	Chemotherapy Administration All	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.154	Radiation Treatment CPT	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.155	Radiation Treatment HCPCS	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.156	Radiation Treatment SNOMEDCT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.157	Radiation Treatment All	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.158	Bipolar Diagnosis Codes	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.159	Telephone Visits SNOMED	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.160	Telephone Visit CPT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.161	Telephone Visits All	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.162	Adolescent depression screening assessment	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.163	Adult depression screening assessment LOINC	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.165	Referral for Depression Adult	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.166	Referrals for Adolescent Depression	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.167	Follow Ups for Adolescent Depression	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.168	FollowUps for Adult Depression	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.169	Depression Screen Declined for Medical Reason	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.170	Physical Therapy Evaluations SNOMEDCT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.171	Physical Therapy Evaluation CPT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.172	Physical Therapies Evaluations	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.173	Non Opioid Analgesics	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.174	Adjuvant Analgesics	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.176	Lung Cancer ICD9	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.177	Lung Cancer ICD10	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.178	Lung Cancer	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.179	Prior Therapies for Osimertinib	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.18	Stage IA	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.181	Plan of Care for Pain	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.182	All Antineoplastic Agents	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.183	Locally Advanced NSCLC Stage Group	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.185	Localized NSCLC Stage Group SNOMED	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.186	Radiation Treatment Management	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.187	Plan of Care	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.188	Documentation of Plan of Care	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.189	Pain Present	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.19	Stage IB	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.190	Localized NSCLC Stage Group NCIM	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.192	Localized NSCLC Stage Group	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.193	Advanced NSCLC Stage Group	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.194	NSCLC M Stage (metastatic)	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.195	NSCLC T Stage	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.196	NSCLC N Stage	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.197	SCLC and rarer lung cancer histology	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.198	EGFR Gene	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.199	EGFR Gene Interpretation Positive SNOMED	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.20	Stage IIA	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.200	EGFR Gene Interpretation Positive LOINC	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.201	EGFR Gene Interpretation Positive	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.202	EGFR Osimertinib Molecular Variants	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.203	EGFR Generic Molecular Variant NCIM	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.204	EGFR Generic Molecular Variant SNOMED	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.205	EGFR Generic Molecular Variant LOINC	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.206	EGFR Molecular Variants Osimertinib PM	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.207	Osimertinib	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.208	Pemetrexed	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.209	Radiation Treatment Management SNOMEDCT	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.21	Stage IIB	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.210	Radiation Treatment Management Codes	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.211	Radiation Treatment Delivery CPT	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.212	77427 Management Code	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.213	Radiation Treatment Delivery HCPCS	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.214	Radiation Treatment Delivery NCIM	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.215	Radiation Treatment Delivery SNOMED	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.216	Radiation Treatment Delivery	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.217	MET Gene Test	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.219	Tepotinib	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.22	Stage IIIA	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.220	MET Positive gene interpretation	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.227	MET Exon 14 skipping molecular variant	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.23	Stage IIIB	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.233	test43	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.234	ROS1 Molecular Variants Repotrectinib PM	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.235	ROS1 Repotrectinib Molecular Variants	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.236	ROS1 Negative (geneinterpretation) SNOMEDCT	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.237	ROS1 Negative (geneinterpretation) NCI	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.238	ROS1 Negative (geneinterpretation) SNOMEDCT,NCI	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.239	ROS1 Positive (geneinterpretation)	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.24	Stage IIIC	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.240	ROS1 results (HGNC)	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.241	ROS1 Gene Rearrangement	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.246	RET Negative (geneinterpretaion) NCI	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.247	RET Negative (geneinterpretaion) SNOMEDCT,NCI	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.248	RET Fusion Molecular Variants	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.25	ESR1 Gene Test	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.250	Repotrectinib Value set	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.251	Amivantamab	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.252	Alectinib Drug	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.253	Gemcitabine Drug Value set	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.254	vinorelbine Drug	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.255	NSCLC_Tumor_resection SNOMEDCT	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.256	NSCLC_Tumor_resection CPT	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.257	NSCLC_Tumor_resection SNOMEDCT CPT	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.258	ALK results (HGNC)	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.259	ALK Positive (geneinterpretation) SNOMED	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.26	ESR1 Genetic Mutation	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.260	ALK Positive (geneinterpretation) NCI	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.261	ALK Positive (geneinterpretation) SNOMEDCT NCI	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.262	ALK Negative (geneinterpretation) SNOMEDCT	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.263	ALK Negative (geneinterpretation) NCI	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.264	ALK Negative (geneinterpretation) SNOMEDCT NCI	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.265	Locoregional Sites	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.266	NSCLC N2 Stage	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.267	NSCLC N1 Stage	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.268	NSCLC N0 Stage	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.269	NSCLC T3_T4 Stage	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.27	Genetic Test Finding	active	2023-09	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.270	NSCLC T2 Stage	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.271	NSCLC T1 Stage	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.272	Locally_Advanced_Metastatic_NSCLC Stage Group	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.273	Localized_Inclusion_NSCLC Stage Group	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.274	Localized_Exclusion_NSCLC Stage Group	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.275	tarlatamab dlle	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.276	Extensive SCLC Stage Group SNOMEDCT	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.277	Extensive SCLC Stage Group NCIM	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.278	Extensive SCLC Stage Group	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.279	Localized SCLC Stage Group	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.280	SCLC M Stage (metastatic)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.281	SCLC T Stage	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.282	SCLC N Stage	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.283	SCLC histology (to include those patients)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.284	Binimetinib	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.285	Encorafenib	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.286	Encorafenib PM Molecular variant	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.288	BRAF Positive (geneinterpretation)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.289	BRAF test (HGNC)	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.292	Prior therapy for Amivantamab	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.293	ENHERTU Drug	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.294	Metastatic_Solid_Cancer_Stage Group SNOMED CT	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.295	Locally_Advanced_Solid_Cancer_Stage Group SNOMED CT	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.296	Localized_Solid_Cancer_Stage Group SNOMED CT	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.297	Solid cancer M Stage (metastatic)	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.298	Solid Cancer T Stage	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.299	Solid Cancer N Stage	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.302	HER2_IHC_Positive	active	2024-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.303	HER2 Negative (geneinterpretation/Labtestvalue) SNOMED	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.304	HER2 Negative (geneinterpretation/Labtestvalue) LOINC	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.305	HER2 Negative (geneinterpretation/Labtestvalue) NCI	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.307	HER2 Negative (geneinterpretation/Labtestvalue)	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.308	Solid Cancer Diagnosis ICD 9	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.309	Solid Cancer Diagnosis SNOMED CT	active	2024-07	us	hl7